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Experimentalstudiesshowthatthehemeoxygenase/carbonmonoxidesystem(HO/CO)playsanimportantroleinthehomeostasis
of circulation and in the pathophysiology of hypertension. No data are available on its role in the control of peripheral circulation
in humans. We evaluated the eﬀects of inhibition of HO with stannous mesoporphyrin IX (SnMP) (200µM) locally administered
by iontophoresis, on human skin blood ﬂow, evaluated by laser-Doppler ﬂowmetry, in the presence and absence of nitric oxide
synthase (NOS) inhibition with L-NG-Nitroarginine methyl ester (L-NAME) (100µM ) .W ea l s oe v a l u a t e dt h ee ﬀect of HO
inhibition on vasodilatation induced by acetylcholine (ACh) and vasoconstriction caused by noradrenaline (NA). SnMP and L-
NAMEcausedasimilar20–25%decreaseinskinﬂow.Afternitricoxide(NO)inhibitionwithL-NAME,HOinhibitionwithSnMP
caused a further 20% decrease in skin perfusion. SnMP decreased vasodilatation induced by ACh by about 70%, while it did not
aﬀectvasoconstriction toNA.Inconclusion,HO/COparticipatesinthecontrolofperipheral circulation,independentlyfromNO,
and is involved in vasodilatation to ACh.
1.Introduction
Carbon monoxide (CO) is physiologically produced in the
arterial wall by the action of heme oxygenase (HO) on heme.
HO exists in two isoforms: the inducible HO-1, and the
constitutive HO-2 [1, 2].
CO,generatedinendothelialandsmoothmusclelayersof
blood vessels by HO, modulates vascular tone, by inducing
relaxation of vascular smooth muscle cells. Smooth muscle
cell relaxation is obtained by stimulating soluble guanylyl
cyclase (sGC) and by opening large-conductance calcium-
activated K+ channels (BK-Ca) [3]. CO acts on smooth
muscle cells through mechanisms that are also involved in
the action of other vasoactive substances, such as nitric
oxide (NO) and endothelium-derived hyperpolarizing factor
(EDHF) [4, 5]. CO also inhibits the cytochrome P450-
dependent monooxygenase system, with a decrease in 20-
hydroxyeicosatetraenoic acid (20-HETE), which sustains
contractile tone by inhibiting potassium channels [4]. In
normal rats, inhibition of HO with chromium meso-
porphyrin impairs ACh-induced vasorelaxation only when
cyclooxygenase, NO synthase, and sGC are all inhibited,
while it has no eﬀect in baseline condition [3]. Nonetheless,
HO inhibition increases peripheral vascular resistance and
blood pressure in experimental animals, but no data are
available in humans [2, 4].
Aim of this study was to evaluate whether the HO/CO
system participates in the control of peripheral circulation
in humans. We have chosen skin circulation as it is involved
in the control of peripheral resistance and can be estimated
by the laser-Doppler technique, which allows to evaluate not
only skin ﬂow but also the local eﬀects of vasoactive sub-
stances and inhibitors administered locally by iontophoresis.
2. Patients andMethods
The study was performed in 20 normal volunteers, age 24–
50yr, 12 males and 8 females. An informed consent was2 International Journal of Hypertension
obtained from each subject, and the study was approved by
the institutional local ethical committee.
After at least a 4-hour fast and 10min lying on a bed at
21–24C,alaserDopplerprobewasappliedonthedorsalface
of the 2nd phalanx of the 3rd ﬁnger and skin ﬂow, expressed
as arbitrary units (PFUs), was measured for 5 minutes. The
average value was considered as the basal ﬂow.
After baseline measurement, the HO inhibitor stannous
mesoporphyrin IX (SnMP) (200µM) (Frontiers Scientiﬁc,
Logan, UT, USA) was applied by iontophoresis (four 15-
second infusions at 0.06mA) in the same skin area and its
eﬀects were evaluated, while another probe was measuring
ﬂow in another ﬁnger of the other hand in order to exclude
changes of ﬂow not due to the inhibitor. The eﬀect of the
NOS inhibitor, L-NG-Nitroarginine methyl ester (L-NAME)
(100µM) (Sigma Chemicals, St. Louis, MO, USA), similarly
applied by iontophoresis, was then evaluated on another
ﬁnger. The HO inhibitor SnMP (200µM) was then applied
together with L-NAME and the eﬀect of the two inhibitors
was measured.
The eﬀects of noradrenaline (NA) (10mMol) (Sigma
Chemicals, St. Louis, MO, USA) (four 15-second infusions
at 0.06mA) and of the endothelium-dependent vasodilator,
acetylcholine (ACh) (11mMol) (Sigma Chemicals, St. Louis,
MO, USA) (seven 15-second infusions at 0.06mA, with
45-sec intervals), applied by iontophoresis, were evaluated
in diﬀerent subjects, in the presence or absence of HO
inhibition with SnMP.
Laser Doppler ﬂowmetry gives a semiquantitative assess-
ment of microvascular blood perfusion, reﬂecting perfu-
sion of capillaries, arterioles, venules, and dermal vascular
plexa [6]. Measurements were done using a PeriFlux laser
Doppler ﬂowmeter (LDF) (Periﬂux system 5000, Perimed,
Jarfalla/Stockholm, Sweden). Iontophoresis allows transder-
mal delivery of polar compounds by means of a small
electricalcurrent.Thedeliveryisdoneinthesameareawhere
blood perfusion is measured, allowing the assessment of
microvascular reactivity when blood perfusion is measured
simultaneously.
2.1. Statistical Analysis. Results were shown as mean ± SD.
Diﬀerences among groups were analyzed by Anova and
unpaired Student’s t-test. Statistical signiﬁcance was set at
P<0.05.
3. Results
Skin ﬂow under basal condition was 23 ± 6 PFU and was
stable during the whole experiment, as demonstrated on the
control ﬁnger. Inhibition of HO with SnMP, administered
locally by iontophoresis in the same skin area where the
ﬂow probe was positioned, caused a 20% decrease in skin
ﬂow (Figure 1). A similar decrease was shown after NOS
inhibition with L-NAME (Figure 1), also given locally by
iontophoresis on a diﬀerent ﬁnger. Inhibition of SnMP after
L-NAME almost doubled the decrease in ﬂow (Figure 1).
NA, administered locally by iontophoresis, caused a 42%
reduction in skin ﬂow (Figure 2), while ACh caused a 290%
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Figure 1: Eﬀect of heme oxygenase inhibition with stannous meso-
porphyrin IX (SnMP) (200µM), of nitric oxide synthase inhibition
with L-NG-Nitroarginine methyl ester (L-NAME) (100µM), and
of both, on skin blood ﬂow measured by laser Doppler ﬂowmetry.
SnMP and L-NAME were administered locally by iontophoresis. ∗P
< 0.05 versus baseline; ∗∗P < 0.05 versus L-NAME.
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Figure 2: Eﬀect of heme oxygenase inhibition with stannous meso-
porphyrinIX(SnMP)(200µM)andnitricoxidesynthaseinhibition
with L-NG-Nitroarginine methyl ester (L-NAME) (100µM) on
the vasoconstricting eﬀect of noradrenaline (NA) on skin blood
ﬂow measured by laser Doppler ﬂowmetry. NA, SnMP, and L-
NAMEwerelocallyadministeredbyiontophoresis. ∗P < 0.05versus
baseline.
increase (Figure 3). Inhibition of HO with SnMP, or NOS
with L-NAME, did not aﬀect the response to NA (Figure 2),
while both of them reduced vasodilatation to ACh by about
70% (Figure 3).
4. Discussion
The results of this study show for the ﬁrst time a role of the
HO/CO system in the control of peripheral circulation in
humans.
Skin blood ﬂow is the result of a balance between
vasoconstricting and vasodilating systems. NO is considered
the most important endothelium-dependent vasodilator of
the skin microcirculation and is released in response to ACh
and shear stress. Its synthesis from L-arginine is inhibited byInternational Journal of Hypertension 3
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Figure 3: Eﬀect of heme oxygenase inhibition with stannous meso-
porphyrinIX(SnMP)(200µM)andnitricoxidesynthaseinhibition
with L-NG-Nitroarginine methyl ester (L-NAME) (100µM) on
vasodilatation induced by acethylcholine (ACh) in skin circulation
evaluated by laser Doppler ﬂowmetry. ACh, SnMP, and L-NAME
were locally administered by iontophoresis. ∗P < 0.05 versus
baseline; ∗∗P < 0.05 versus Ach.
L-NMMA or L-NAME. Kvandal et al. [6] have shown that
intraarterial infusion of L-NMMA causes a 20% reduction in
skin ﬂow, which could be reversed by l-arginine. L-NMMA;
however, it did not aﬀect skin perfusion raised by ACh.
Our results, although obtained with a diﬀerent technique,
conﬁrm that inhibition of NOS causes a reduction in skin
ﬂow. Furthermore, we showed that NOS inhibition reduced
the vasodilating aﬀect of ACh by about 70%. This diﬀerence
in results is probably related to the diﬀerent method of
administration of the NOS inhibitor, which was given
locally, by iontophoresis in our subjects, and intraarterially
in Kvandal’s study. It is, in fact, possible that the local
administration allows to obtain higher concentrations and,
thus, a higher eﬀect due to a higher inhibition of NOS,
considering that the intraarterial infusion cannot be done
using high doses to avoid the systemic eﬀects. Thus, our
results conﬁrm that cutaneous vascular tone is regulated by
NO.
Treatment of normotensive rats with HO inhibitors
causes elevation of peripheral vascular resistance and blood
pressure,suggestingthatendogenousCOsubservesavasode-
pressor function [7]. The same conclusion was derived from
reports that treatment of hypertensive rats with HO inducers
or substrates reduces blood pressure via a heme oxygenase-
dependent mechanism [8–11]. Also, observations that heme
elicits HO-dependent vasodilation in isolated gracilis muscle
arterioles and tail arteries suggested that CO of vascular
origin can be a mediator of vasodilatory mechanisms.
In our normal subjects, basal skin ﬂow was reduced by
SnMP,eveninthepresenceofNOSinhibitionwithL-NAME.
Thus,itisconceivablethatCOparticipatesinthephysiologic
control of tone in the peripheral circulation and may also
be involved in pathophysiology. CO-induced cell signaling
has been proposed to occur via sGC activation, although
CO is far less eﬀective at activating sGC than is NO [2, 5].
CO also activates BK-Ca channels in smooth muscle cells
from a variety of diﬀerent vascular beds, including cerebral
and tail arteries [12]. In isolated vascular smooth muscle
cells, CO-induced BK-Ca channel activation is not blocked
byinhibitorsofsGCandisnotreproducedbyotherproducts
of HO-mediated heme metabolism. Thus, vascular smooth
muscle cell HO-derived CO, or exogenous CO, activates
arterial smooth muscle cell BK-Ca channels either directly or
via interaction with channel-associated regulatory elements.
Furthermore, NO and CO activate vascular smooth muscle
cell BK-Ca channels via distinct mechanisms that involve
eﬀectsondiﬀerentchannelsubunits[2,3,5],thusexplaining
the additive eﬀect of NOS and HO inhibition on skin ﬂow.
The eﬀect of ACh was also blunted by HO inhibi-
tion, suggesting that the NO-independent and prostacyclin-
independent component of vasodilatation to ACh is medi-
ated, at least in part, by the HO/CO system.
We have previously shown that HO inhibition in
mesenteric microvessels from normal rats, pretreated with
indomethacin, L-NAME, and also the cGMP inhibitor 1H-
[1,2,4]oxadiazolo[4, 3-a] quinoxalin-1-one (ODQ), causes
a decrease in the vasodilating eﬀect of ACh [3]. This eﬀect
wassimilartothatofiberiotoxin,aBK-Cachannelsinhibitor.
Thus, it is conceivable that the HO/CO system participates
in the homeostasis of vascular tone by stimulating BK-Ca
channels, although it is well known that other mechanisms
are possible, like inhibition of 20HETE synthesis, decrease of
ROS [4].HOinhibitiondidnotincreasethevasoconstricting
response to NA. This last result is similar to what shown
in the rat mesenteric circulation [13]. It is possible that an
increased response to NA by HO inhibition is masked by an
increase in NO, prostacyclin, or other vasodilators, but there
has also to be considered the possibility that the degree of
vasoconstriction induced by NA was the highest which could
be obtained with a vasoconstrictor (a mean of 42%) in the
skin and, thus, any increase could not be demonstrated. On
the contrary, when HO is induced, like in cirrhosis or after
transfection with the HO-1 gene [13], the hyporeactivity to
vasoconstrictors can be reversed by inhibition of HO.
The results of this study may have therapeutic implica-
tions. While inhibition of HO may be useful for treatment of
vasodilatation and hyperdynamic circulation, like in sepsis
or cirrhosis, in conditions of increased peripheral resistance,
like hypertension, or of vasoconstriction, like angina or
ischemic arteriopathy, HO induction or supplementation of
CO could be employed.
In conclusion, in normal physiological conditions, in
humans, the HO/CO system participates in the control of
peripheral circulation, besides NO, and also mediates, in
part, the endothelium-dependent vasodilatation to ACh.
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